Esophageal Cancer

>

Latest News

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer

June 2nd 2024

The combination of perioperative chemotherapy plus FLOT improved overall survival vs neoadjuvant chemoradiation in patients with resectable esophageal cancer.

Results from the phase 3 RATIONALE 302 trial led to the approval of tislelizumab for patients with unresectable or metastatic esophageal squamous cell carcinoma.
FDA Approves Second-Line Tislelizumab Monotherapy in Esophageal Cancer

March 14th 2024

Trimodality Therapy Leads to QOL Improvement in Esophageal Cancer
Trimodality Therapy Leads to QOL Improvement in Esophageal Cancer

January 24th 2024

Data from the phase 3 SKYSCRAPER-08 trial may support tiragolumab plus atezolizumab and chemotherapy as an alternative frontline treatment option for those with locally advanced or metastatic esophageal squamous cell carcinoma.
Tiragolumab Combo Improves PFS/OS Vs Chemo in Esophageal Cancer

January 20th 2024

Neoadjuvant camrelizumab plus chemotherapy may hold promise as a standard of care in locally advanced esophageal squamous cell carcinoma, according to Yin Li, MD.
Camrelizumab/Chemo Improves pCRs Vs Chemo in Locally Advanced ESCC

January 19th 2024